Fig.1




Fig.2





Fig.3



SEQUENCE LISTING

<110> TAKARA BIO INC.

<120> Vector for gene therapy

<130> 668252

<150> JP 2007-112178
<151> 2007-04-20

<150> JP 2007-138889
<151> 2007-05-25

<150> JP 2007-268310
<151> 2007-10-15

<150> JP 2008-025248
<151> 2008-02-05

<160> 12

<170> PatentIn version 3.3

<210> 1
<211> 111
<212> PRT
<213> Escherichia coli

<400> 1

Met Val Ser Arg Tyr Val Pro Asp Met Gly Asp Leu Ile Trp Val Asp
1 5 10 15

Phe Asp Pro Thr Lys Gly Ser Glu Gln Ala Gly His Arg Pro Ala Val
20 25 30

Val Leu Ser Pro Phe Met Tyr Asn Asn Lys Thr Gly Met Cys Leu Cys
35 40 45

Val Pro Cys Thr Thr Gln Ser Lys Gly Tyr Pro Phe Glu Val Val Leu
50 55 60

Ser Gly Gln Glu Arg Asp Gly Val Ala Leu Ala Asp Gln Val Lys Ser
65 70 75 80

Ile Ala Trp Arg Ala Arg Gly Ala Thr Lys Lys Gly Thr Val Ala Pro
85 90 95

Glu Glu Leu Gln Leu Ile Lys Ala Lys Ile Asn Val Leu Ile Gly
100 105 110

<210> 2
<211> 336
<212> DNA
<213> Artificial

<220>
<223> Synthetic DNA encoding MazF.

<400> 2
atggtaagcc gatacgtacc cgatatgggc gatctgattt gggttgattt tgacccgacc 60

aaaggtagcg agcaagctgg ccatcgtcca gctgttgtcc tgagtccttt catgtataat 120

aataaaaccg gtatgtgtct gtgtgttcct tgtaccacgc aatcaaaagg atatccgttc 180

gaagttgttt tatccggtca ggaacgtgat ggcgtagcgt tagctgatca ggtaaaaagt 240

atcgcctggc gggcaagagg agcaacgaag aaaggaaccg ttgccccaga ggaactgcag 300

ctcattaaag ccaaaattaa cgtactgatt ggttaa 336

<210> 3
<211> 26
<212> DNA
<213> Artificial

<220>
<223> Primer to amplify HIV-LTR-MazF cassette.

<400> 3
cggccgctgg aagggctaat ttggtc 26

<210> 4
<211> 34
<212> DNA
<213> Artificial

<220>
<223> Primer to amplify HIV-LTR-MazF cassette.

<400> 4
gcggccgctt aaccaatcag tacgttaatt ttgg 34

<210> 5
<211> 29
<212> DNA
<213> Artificial

<220>
<223> Primer to amplify pA fragment.

<400> 5
gcggccgcgg gggaggctaa ctgaaacac 29

<210> 6
<211> 26
<212> DNA
<213> Artificial

<220>
<223> Primer to amplify pA fragment.

<400> 6
acgcgtggct atggcagggc ctgccg 26

<210> 7
<211> 39
<212> DNA
<213> Artificial

<220>
<223> Primer to amplify pPGK fragment.

<400> 7
acgcgtgcgg ccgcagatct aattctaccg ggtagggga 39

<210> 8
<211> 39
<212> DNA
<213> Artificial

<220>
<223> Primer to amplify pPGK fragment.

<400> 8
ctcgaggcgg cgcggatccc tgcaggtcga aaggcccgg 39

<210> 9
<211> 34
<212> DNA
<213> Artificial

<220>
<223> Primer to amplify LNGFR fragment.

<400> 9
gcgctgatca gaattcgccg cggccagctc cggc 34

<210> 10
<211> 31
<212> DNA
<213> Artificial

<220>
<223> Primer to amplify LNGFR fragment.

<400> 10
gcgcctcgag tctagaggat ccccctgttc c 31

<210> 11
<211> 82
<212> PRT
<213> Escherichia coli

<400> 11

Met Ile His Ser Ser Val Lys Arg Trp Gly Asn Ser Pro Ala Val Arg
1 5 10 15

Ile Pro Ala Thr Leu Met Gln Ala Leu Asn Leu Asn Ile Asp Asp Glu
20 25 30

Val Lys Ile Asp Leu Val Asp Gly Lys Leu Ile Ile Glu Pro Val Arg
35 40 45

Lys Glu Pro Val Phe Thr Leu Ala Glu Leu Val Asn Asp Ile Thr Pro
50 55 60

Glu Asn Leu His Glu Asn Ile Asp Trp Gly Glu Pro Lys Asp Lys Glu
65 70 75 80

Val Trp

<210> 12
<211> 249
<212> DNA
<213> Escherichia coli

<400> 12
atgatccaca gtagcgtaaa gcgttgggga aattcaccgg cggtgcggat cccggctacg 60

ttaatgcagg cgctcaatct gaatattgat gatgaagtga agattgacct ggtggatggc 120

aaattaatta ttgagccagt gcgtaaagag cccgtattta cgcttgctga actggtcaac 180

gacatcacgc cggaaaacct ccacgagaat atcgactggg gagagccgaa agataaggaa 240

gtctggtaa 249